Figure 2 .

In the overall population regardless of brain metastasis status, Kaplan-Meier estimates for (A) PFS by prior capecitabine; (B) OS by prior capecitabine; (C) PFS by hormone receptor (HR) status; (D) OS by HR status; (E) PFS by brain metastasis status in; (F) OS by brain metastasis status

Ro et al. BMC Cancer 2012 12:322   doi:10.1186/1471-2407-12-322
Download authors' original image